Notice of results

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that it will release its interim results for the six months ended 30 June 2018 on Wednesday 19 September 2018.

Enquiries:

EKF Diagnostics Holdings plc Christopher Mills, Non-Executive Chairman Julian Baines, CEO Richard Evans, Finance Director and COO	www.ekfdiagnostics.com Tel: 00 44 29 2071 0570
N+1 Singer (Nomad & Broker) Aubrey Powell / Lauren Kettle / George Tzimas (Corporate Finance) Tom Salvesen (Corporate Broking)	Tel: 020 7496 3000
Walbrook PR Limited Paul McManus Lianne Cawthorne	Tel: 020 7933 8780 or Mob: 07980 541 893 / 07584 391 303

Back to Listing Previous Next

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

EKF Quo-Test supports improved medical management of diabetic retinopathy patients

SensLab is sponsoring the 36th Leipzig Triathlon

SensLab, an EKF Diagnostics company, will be testing triathletes lactate levels at the 36^th Leipzig Triathlon to be held at Kulkwitzer on the 28^th July 2019.

Bugs Runny: New study identifies bugs that help runners

A recent article in Nature Medicine by Scheiman et al has identified a strain of gut microbes present in marathon runners that improves run times. The scientists at Harvard and the Joslin Institute took poop samples from 15 runners at the 2015 Boston marathon.

EKF at AACC - Anaheim, California 2019

EKF's DiaSpect Tm hemoglobin analyzer supports anemia study in resource limited West Africa

Battery powered point-of-care analyzer demonstrated as ideal for operation in extreme temperatures and remote areas.